HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
7.54
+0.14 (1.89%)
Apr 29, 2025, 4:00 PM EDT - Market closed

Company Description

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.

The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which is in Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.

It also develops HCW9201 + HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer.

The company has a license agreement with Wugen Inc. for two molecules constructed with its TOBI platform; and a license, research and co-development agreement with WY Biotech for its preclinical molecules which were built with the TRBC platform technology.

HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc.
HCW Biologics logo
Country United States
Founded 2018
IPO Date Jul 20, 2021
Industry Biotechnology
Sector Healthcare
Employees 36
CEO Hing Wong

Contact Details

Address:
2929 North Commerce Parkway
Miramar, Florida 33025
United States
Phone 954 842 2024
Website hcwbiologics.com

Stock Details

Ticker Symbol HCWB
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
IPO Price $8.00
CIK Code 0001828673
CUSIP Number 40423R105
ISIN Number US40423R1059
Employer ID 82-5024477
SIC Code 2834

Key Executives

Name Position
Dr. Hing C. Wong Ph.D. Founder, Chief Executive Officer, Director and Secretary
Rebecca Byam CPA, M.B.A. Chief Financial Officer
Dr. Peter Rhode Ph.D. Chief Scientific Officer and Vice President of Clinical Operations
Nicole Valdivieso Esq. Vice President of Legal Affairs
Lee D. Flowers Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Apr 28, 2025 DEF 14A Other definitive proxy statements
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 22, 2025 8-K Current Report
Apr 16, 2025 EFFECT Notice of Effectiveness
Apr 16, 2025 424B3 Prospectus
Apr 14, 2025 8-K Current Report
Apr 7, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Apr 1, 2025 8-K Current Report
Apr 1, 2025 8-K Current Report